Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Review of Takeda’s Febuxostat New Drug Application Continues Past PDUFA Date – FDA has not completed routine investigator site and CRO vendor inspections

By Pharmaceutical Processing | January 19, 2009

Takeda Pharmaceutical Company Limited has announced that Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, received notification from the U.S. Food and Drug Administration (FDA) that FDA will not be able to complete its review of the febuxostat New Drug Application (NDA) by the Prescription Drug User Fee Act (PDUFA) date of January 18, 2009. “The FDA raised no issues with the NDA submission or the data included in it, rather FDA stated that due to its inability to complete routine inspections at investigator sites and at a Clinical Research Organization vendor involved in the development of febuxostat, the PDUFA date for febuxostat would be missed by the FDA,” said Dean Sundberg, senior vice president, regulatory affairs at Takeda Global Research & Development Center, Inc. “Takeda has taken all necessary steps and provided all necessary information at this point in the NDA review process and we await FDA’s completion of these routine inspections and look forward to receiving a final approval date for febuxostat.” Febuxostat is currently under review with FDA for once-daily, oral treatment of hyperuricemia in patients with gout. The NDA for febuxostat included data from multiple clinical trials involving more than 4,000 patients. In November 2008, FDA’s Arthritis Advisory Committee recommended febuxostat for approval by a vote of 12-0 with one panel member abstaining. Takeda licensed febuxostat from Teijin Pharma Limited (Teijin Pharma), based in Tokyo, Japan.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE